Chembio Diagnostics's revenue for the
three
months ended in Dec. 2022 was $9.16 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2022 was $48.34 Mil.
Chembio Diagnostics's Revenue per Share for the
three
months ended in Dec. 2022 was $0.25.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $1.53.
Warning Sign:
Chembio Diagnostics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Chembio Diagnostics was -1.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -9.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -8.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Chembio Diagnostics's highest 3-Year average Revenue per Share Growth Rate was 26.30% per year. The lowest was -59.90% per year. And the median was -7.80% per year.
Chembio Diagnostics Revenue Historical Data
The historical data trend for Chembio Diagnostics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chembio Diagnostics's Revenue
For the Diagnostics & Research subindustry, Chembio Diagnostics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chembio Diagnostics's Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's Revenue distribution charts can be found below:
* The bar in red indicates where Chembio Diagnostics's Revenue falls into.
Chembio Diagnostics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Chembio Diagnostics Revenue Related Terms
Thank you for viewing the detailed overview of Chembio Diagnostics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Chembio Diagnostics (Chembio Diagnostics) Business Description
Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CEMI has been successfully added to your 